Status:
COMPLETED
Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model
Lead Sponsor:
Stallergenes Greer
Conditions:
Allergic Rhinitis Due to House Dust Mite
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the effect of 3 doses of sublingual house dust mite (HDM) tablets versus placebo in the change from baseline of rhinitis total symptom score during the allergen ...
Eligibility Criteria
Inclusion
- history of HDM rhinitis allergy for \> 1 year
- sensitized to D. pteronyssinus and/or D. farinae
- RTSS \>= 6 at least 2 time points during allergen challenge session
Exclusion
- co sensitization to other allergen than HDM
- FEV1 \< 80%
- Asthma GINA \> 1
Key Trial Info
Start Date :
December 8 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 19 2012
Estimated Enrollment :
355 Patients enrolled
Trial Details
Trial ID
NCT01527188
Start Date
December 8 2010
End Date
September 19 2012
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cetero Research
Mississauga, Ontario, Canada, L4W 1N2